Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity
- 31 May 2013
- journal article
- Published by Elsevier BV in Biomaterials
- Vol. 34 (16), 4089-4097
- https://doi.org/10.1016/j.biomaterials.2013.02.019
Abstract
No abstract availableKeywords
Funding Information
- Canadian Institutes of Health Research
- Alberta Cancer Foundation
This publication has 24 references indexed in Scilit:
- Active methods of drug loading into liposomes: recent strategies for stable drug entrapment and increasedin vivoactivityExpert Opinion on Drug Delivery, 2011
- Her2-targeted pegylated liposomal doxorubicin: Retention of target-specific binding and cytotoxicity after in vivo passageJournal of Controlled Release, 2009
- Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptideInternational Journal of Pharmaceutics, 2009
- Factors affecting toxicity and efficacy of polymeric nanomedicinesToxicology and Applied Pharmacology, 2008
- Beyond drug deliveryNature Nanotechnology, 2008
- Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymersProceedings of the National Academy of Sciences of the United States of America, 2008
- Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptorsMolecular Cancer Therapeutics, 2006
- Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimeticJournal of Controlled Release, 2005
- Preclinical Evaluation of the Breast Cancer Cell-Binding Peptide, p160Clinical Cancer Research, 2005
- Influence of Targeting Ligand Flexibility on Receptor Binding of Particulate Drug Delivery SystemsBioconjugate Chemistry, 2003